Thursday 25 February 2010
Cancer Research UK Press Release
Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy.
Researchers at trial centres across the UK and coordinated at Oxford University will test a new treatment called Radio-embolisation, a form of internal radiotherapy that...
A group of Brisbane grandfathers have stripped down to their jocks, dancing for all the world to see, in an online bid to raise bowel cancer awareness.
Posted on YouTube, the Rotary Bowelscan video Bowel Cancer - You are Never too Young features the backsides of four men aged 50 to 80 and a toned woman in her 40s.
Video star John Kolcze, 61, says the idea is to spread the message...
The European Union has recommended Xeloda be used to treat early colon cancer.
Patients should be treated with the drug, manufactured by Roche Holding AG, alongside oxaliplatin (Eloxatin), following surgery for the cancer, an EU committee recommended.
Xeloda is already approved for a variety of treatments and marketed in over 100 countries, with total sales of 1.3 billion Swiss francs in 2009.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey (CINJ) are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients. CINJ is a Center...
Reversing Resistance to Sunitinib: Findings May Help Patients With Deadly Kidney Cancer
ScienceDaily (Feb. 19, 2010) — Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.
